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No special nursing precautions were taken
either during the hospitalization or after the
death, and the body was transferred to Kikwit to
be buried. On April 30, another nun who took care of
the index patient during the night of April 23
became ill with fever, headache, and myalgia. Over
the next few days, the second patient had a clinical
picture identical to that of the index patient,
including high fever, severe asthenia, vomiting,
hiccups, and diarrhea. On May 5, epistaxis and
coagulation abnormalities developed, followed by
other clinical signs of the hemorrhagic syndrome.
The second patient was transferred to Kikwit
General Hospital, where she died 6 days later. A
laboratory confirmation of Ebola hemorrhagic fever
was made on a blood specimen collected on May 5
and sent to Special Pathogens Branch (Centers for
Disease Control and Prevention, Atlanta, GA).
These cases of unrecognized Ebola hemor-
rhagic fever were part of the hospital outbreak
that precipitated and mobilized international
community efforts (2). Retrospectively, the
clinical symptoms observed were typical of Ebola
hemorrhagic fever (3,4) and were described again
in subsequent patients during this outbreak (5).
In tropical Africa, the presence of hemorrhagic
symptoms in the course of a febrile illness should
raise the possibility of one of the viral hemorrhagic
fever diseases. In viral hemorrhagic fevers,
maculopapular rash is constantly observed only in
filovirus disease. Typically, the clinical laboratory
findings include an early lymphopenia and marked
thrombocytopenia. Containment and barrier nurs-
ing procedures should be initiated until the
diagnosis of viral hemorrhagic fever can be ruled
out. The index patient described here was the third
patient transferred from Kikwit General Hospital
in less than 1 month to die of a hemorrhagic
illness after a few days of an unexplained febrile
syndrome. Two patients were health-care
workers in Kikwit General Hospital. This cluster
of hemorrhagic illness and possible human-to-
human transmission, particularly among hospi-
tal staff, was (and should always be) sufficient to
suspect a viral hemorrhagic fever. The laboratory
confirmation of this presumptive diagnosis was
the clenching factor in the multinational effort in
Kikwit.
Marie-Jo Bonnet, Philippe Akamituna, and
Anicet Mazaya
Mosango General Hospital, Kikwit, République
Démocratique du Congo
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Classification of Reactive Arthritides
To the Editor: We read with interest J.A.
Lindsay’s article on sequelae of foodborne
disease (1). However, we believe that there are
errors in the classification of the reactive
arthritides. Lindsay states that ankylosing
spondylitis (AS) is a “rheumatoid inflammation
of synovial joints and entheses within and
distal to the spine.” Although not the primary
focus of the article, the classification and
etiopathogeneses of rheumatoid arthritis (RA)
and the seronegative spondyloarthropathies,
including AS, should be clarified. The term
spondylitis, from the Greek spondylos, for
vertebra, means inflammation of the vertebrae.
The term rheumatoid is generally taken to
apply to rheumatoid arthritis, while rheumatic
is a more general term applying to all
connective tissue diseases.
AS is a chronic, systemic, inflammatory
disorder primarily affecting the axial skeleton,
with sacroiliac joint involvement as its hallmark.
Back pain is the first clinical manifestation in
approximately 75% of the patients (2). The
backache is usually insidious in onset, dull, and
difficult to localize. After several months, it
generally becomes bilateral and persistent. The
ache is often worse in the morning or after
periods of inactivity and improves with move-511 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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ment. The course is highly variable. Involvement
of peripheral joints other than hips and shoulders
is uncommon.
AS is strongly associated with human
leukocyte antigen (HLA) B27, a major histocom-
patibility complex (MHC) class I allele, and may
show familial aggregation. More than 90% of
patients with AS have the HLA-B27 allele (3).
HLA-B27 is believed to be directly involved in
disease pathogenesis. Transgenic rats expressing
human HLA-B27 develop a broad spectrum of
disease closely resembling human disease. These
rats have peripheral and axial arthritis,
gastrointestinal inflammation, and diarrhea.
Psoriatic-like skin changes and inflammation of
the heart and male genitalia are also seen.
Histologically, the joint, gut, skin, and heart
lesions resemble those seen in HLA-B27-related
disease in humans (4).
The inflammatory process in AS involves the
synovial and cartilaginous joints, as well as the
osseous attachments of tendons and ligaments
(entheses). Much of the skeletal pathology of AS can
be explained by the changes that take place at the
entheses. After an initial inflammatory, erosive
process involving the entheses, there is healing in
which new bone is formed. The final outcome of this
process is an irregular bony prominence with
sclerosis of the adjacent cancellous bone (5). This
can be contrasted with the pathology of RA, in
which there is a greater tendency to affect
cartilaginous joints such as the intervertebral
discs and symphysis pubis. The process in RA is
one of bony erosion rather than new bone
formation.
The term ankylosing spondylitis, derived
from the Greek for “bent spinal vertebrae,” by
definition requires exclusion of the other
spondyloarthropathies, such as Reiter syndrome
and reactive arthritides due to enteric (or
urogenital) organisms. Spondylitis may occur in
reactive arthritis, psoriatic arthritis, or the
arthropathy associated with inflammatory bowel
disease, but is less common in these diseases
(approximately 50% in reactive arthritis, 20% in
enteric arthritis or psoriatic arthritis). All of
these diseases can be viewed as seronegative
spondyloarthropathies in that, by definition,
rheumatoid factor is not present.
RA is a systemic autoimmune disorder of
unknown etiology. It is a chronic symmetric
arthropathy of peripheral joints, associated with
erosive synovitis. Enthesopathy is generally not
found. The majority of patients have elevated
titers of serum rheumatoid factor, as opposed to
the seronegative spondyloarthropathies. Spinal
involvement in RA is seen but most often involves
the cervical spine. The pathogenesis of the spinal
disease is that of synovitis of the odontoid-atlas
joints. The major HLA association is with HLA-
DR4, an MHC class II allele.
Reactive arthritis is so named because it is
felt that the arthritis and other inflammatory
manifestations are an immune reaction to a
distant infection. There is an association with
HLA-B27 but less so than that found in AS (60%
to 80%, compared with more than 90% in AS).
While bacterial antigens can be found within the
joint, the offending infectious process most often
subsides before the onset of arthritis, and no
living organisms are found in the joint (2). In
many cases, no infectious trigger can be
identified. Persistence of microbial antigens has
been demonstrated and is likely to play a
prominent role in the pathogenesis of acute and
chronic inflammation. Antigens to several
gastrointestinal pathogens have been isolated
from the synovial fluid in patients with reactive
arthritis. Salmonella, Shigella, Yersinia, Campy-
lobacter, and Borrelia are the most common
pathogens capable of initiating reactive arthritis
(2). The arthritis is generally an asymmetric
oligoarthritis predominantly affecting the lower
extremities and typically develops 6 to 14 days
after a bout of diarrhea. However, onset can occur
up to 3 months later. Diarrhea can also be absent,
and there is no relationship between the severity
of the arthritis and the severity of the diarrhea.
Reiter syndrome is in fact a reactive arthritis.
In 1916, Hans Reiter described a triad of arthritis,
urethritis, and conjunctivitis in a soldier with
dysentery. However, the disease was actually first
described by Sir Benjamin Brodie in the early 1800s
(6). The complete triad is actually seen in only a
minority of patients. Arthritis develops 1 to 3 weeks
after the diarrhea or urethritis. It is generally
asymmetric, involving large joints, especially in the
lower extremities. The term Reiter syndrome
actually refers only to the triad of arthritis,
urethritis, and conjunctivitis. Reiter syndrome is
both clinically and historically more accurately
termed reactive arthritis. Nevertheless, the term
reactive arthritis does not reflect the systemic
nature of the disease.
In summary, while both reactive arthritis
and ankylosing spondylitis are seronegative512 Emerging Infectious Diseases Vol. 4, No. 3, July–September 1998
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spondyloarthropathies, they are separate enti-
ties. Both are distinct from rheumatoid arthritis.
Darren R. Blumberg and Victor S. Sloan
Robert Wood Johnson Medical School, New
Brunswick, New Jersey, USA
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Reply to Drs. Blumberg and Sloan
To the Editor: I concur with your comments. After
reviewing the literature related to foodborne
disease, it appears that the original classification
of reactive arthritides has been in error for some
time. I certainly appreciate the correction.
James A. Lindsay
University of Florida, Gainesville, Florida, USA
Cost of Blood Screening
To the Editor: In reference to G.A. Schmunis’
article on the risk for transfusion-transmitted
infections in Central and South America (1), I
would like to comment on the cost of blood
screening. In a screening program, the objective
is to have safe blood units, not to assess the
prevalence of different infections among poten-
tial or actual donors. Thus, while acknowledging
all infections present in a given donor or potential
donor is not required, detecting at least one of the
infections that would make a donor noneligible is. If
samples from every potential donor are subjected
(by default) to all the tests, information on every
infection present is provided, and the cost of
screening this donor is the sum of the cost of every
test applied; in this case, both the information and
the cost are greater than necessary.
Information on the prevalence of bloodborne
infections among the general population or,
preferably, among potential donors (particularly
where professional donors are frequent) along
with information on the costs of the tests to be
used can form the basis of a stepwise screening
scheme. Tests for infections with the highest
prevalence would be applied first. For example,
in many areas of Peru, using the Venereal
Disease Research Laboratory (VDRL) test (for
screening Treponema pallidum infection) first
would reduce the number of samples to be
subjected to other more expensive and often less
available tests (e.g., HIV enzyme-linked
immunosorbent assay [ELISA] or hepatitis C
virus [HCV] ELISA); in others areas, a test for
hepatitis B virus antigen (HBsAg) should be used
before HIV ELISA. The reduction in cost
provided by stepwise screening will depend on
the prevalences of the more frequent infections
and the frequency of concurrent infections.
The questionnaires applied to candidate
donors should be validated, and the benefit of
using them should be assessed. In most settings,
candidate donors are either ignorant of their
status as carriers of bloodborne infection or ready
to deny it; therefore, the questionnaire is of little
use. In some cases candidate donors are turned
down because of “hepatitis history” when in fact
they have not had bloodborne hepatitis.
Finally, screening tests seem to be quite more
expensive than reported in Table 4 of the Schmunis
article. In Lima, at a ministry of health facility,
some prices are as follows: HIV ELISA US$12.50,
VDRL US$6.40, HBsAg US$13.90.
O. Jaime Chang
Instituto Nacional de Salud, Ministerio de Salud,
Lima, Peru
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